Strategic Biomanufacturing Partner For Multispecific Antibodies

By Youngsun Kim, Senior Director of Multi-modality MSAT, Jina Kim, Director of the Ab Technology Discovery, and Busol Park, Senior Scientist of MSAT

Multispecific antibodies are a revolutionary leap in biologic therapeutics, enabling simultaneous targeting of multiple antigens or pathways. This enhanced precision against intricate disease mechanisms offers significant potential for better outcomes in oncology, immunology, and beyond. However, their intricate structure presents considerable scientific, technical, and regulatory hurdles that demand careful management for successful development and market entry.

Distinct from conventional monoclonal antibodies, multispecific antibodies necessitate accurate heavy and light chain pairing, optimal protein folding, and reliable expression in host cells. These demands complicate their production, affecting yield, stability, and scalability. Furthermore, as the biopharmaceutical field advances, these sophisticated biologics must be engineered for favorable pharmacokinetics, reduced immunogenicity, and the intended therapeutic impact.

Addressing these complexities requires specialized skills in cell line development, process optimization, and analytical characterization, along with manufacturing facilities equipped for complex biologics. Developers must consider both the design and function of multispecific antibodies and the influence of production methods on quality, regulatory adherence, and cost efficiency.